Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 410

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 410
---
 |   |        – |   |     |   |        – |   |     |   |  415,043 |   |
| Registered Offering December 2023        |     |   |  1,911,176 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Adhera Assignment and Exchange Agreement |     |   |    899,642 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Exercised                                |     |   |   (155,461 | ) |     |   |  (32,327 | ) |     |   |  (48,491 | ) |     |   | (415,043 | ) |
| As at 31 December 2023                   |     |   |  2,810,818 |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |

The Series A, Series
B and Series C warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for
nil consideration.

Numbers of shares and
share options/ warrants and related exercise/issue prices are after the impact of the 24 March 2023 share consolidation, ADS ratio changes
on 24 March 2023 and 5 July 2023.

In accordance with the
Articles of Association for the Company adopted on 14 June 2023, the share capital of the Company consists of an unlimited number of ordinary
shares of nominal value £0.001 each. Ordinary and deferred shares were recorded as equity.

Rights attaching
to the shares following the incorporation of Biodexa Pharmaceuticals plc

Shares classified
as equity

The holders of ordinary
shares in the capital of the Company have the following rights:

(a) to receive
notice of, to attend and to vote at all general meetings of the Company, in which case shareholders shall have one vote for each share
of which he is the holder; and,

(b) to receive
such dividend as is declared by the Board on each share held.

The holders of both
classes of deferred shares in the capital of the Company:

(a) shall not
be entitled to receive notice of or to attend or speak at any general meeting of the Company or to vote on any resolution